Deerfield Management Company, L.P. (Series C) Homology Medicines, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$12.07 - $19.34 $48.7 Million - $78.1 Million	-4,037,305 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$12.5 - $22.04 $15.1 Million - $26.6 Million	-1,208,333 Reduced 23.04%	4,037,305 $62.7 Million
Q4 2019 Feb 14, 2020	SELL	$11.42 - $22.19 $5.88 Million - $11.4 Million	-514,730 Reduced 8.94%	5,245,638 $109 Million
Q2 2019 Aug 14, 2019	BUY	$18.35 - $30.34 $9.79 Million - $16.2 Million	533,333 Added 10.2%	5,760,368 $113 Million
Q1 2018 May 15, 2018	BUY	$18.66 - $18.7 $97.5 Million - $97.7 Million	5,227,035 New	5,227,035 $97.7 Million

Others Institutions Holding FIXX

# of Institutions

Shares Held

66.2K

Call Options Held

Put Options Held

View Full List

About Homology Medicines, Inc.

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

More about FIXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account